New research initiative on patient preferences

The UK National Institute for Health and Excellence (NICE) launches two year study on patient health preferences.

The UK National Institute for Health and Excellence (NICE) has received a  £120,000 grant from Myeloma UK for a methodological study of patient health preferences. During the course of the two year project, NICE will consult experts, patient groups and global health technology assessment (HTA) leaders.

Read more

By Josepine Fernow, Uppsala University

Last modified:

CONTACT US

X: @IMI_PREFER

LinkedIn

YouTube

  •  
  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
  •  

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).